pp-273 Tablets
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Solid tumor, Metastatic ovary cancer
Clinical stage: Phase 3
Modality: Small molecule
Mechanism & Target: DNA repair pathway modulator
Route & form: Oral
Differentiation: Not disclosed
Manufacturer #39684
A late-stage clinical biopharmaceutical company focused on oncology. Developing a small molecule therapeutic targeting oncology with global development focus. Pipeline positioned for regulatory advancement in key markets.
None